Replimune and Incyte to study cancer combo therapy in CSCC patients

Replimune and Incyte to study cancer combo therapy in CSCC patients

Submitted by admin on August 1, 2023 - 10:06am
Source: 
Clinical Trials Arena
News Tags: 
Replimmune
Incyte
clinical trials
RP1
CSCC
cutaneous squamous cell carcinoma
Headline: 
Replimune and Incyte to study cancer combo therapy in CSCC patients
snippet: 

Replimune Group and Incyte have entered a clinical trial collaboration and supply agreement to study RP1 together with INCB99280 in patients with high-risk, resectable cutaneous squamous cell carcinoma (CSCC).

Do Not Allow Advertisers to Use My Personal information